ERA is collecting FAQs and Advice from National Societies on COVID-19 Vaccination for Kidney Patients
Select and click on a Country to read its National Society’s FAQs and Advice
ERA is collecting these statements in collaboration with the National Societies of Nephrology to provide a service to our website visitors.
Kindly note that these links will take you to a website not owned by ERA. ERA is not responsible for the content or privacy/legal policies of any third-party websites.
Dutch Federation of Nephrology and Dutch Society of Kidney Patients
Turkish Society of Nephrology
Czech Society of Nephrology
The UK Renal Association
The Scottish Renal Association – The Scottish Renal Registry
German Society of Nephrology
Austrian Society of Nephrology
Spanish Society of Nephrology (S.E.N.)
Effective and safe vaccines and continuous infection mitigation strategies are currently the only realistic options to constrain the ongoing COVID-19 pandemic.
COVID-19 vaccines can be considered safe in both dialysis and kidney transplant patients and there should be no big differences in side effects compared to the healthy population.
The benefits of vaccines outweigh their theoretical risks, thus vaccination should not be delayed in KD patients. As yet mRNA as well as viral vector vaccines are acceptable.
Nephrologists need to join forces all over Europe and conduct new studies with similar protocols about the efficacy and safety of all currently available COVID-19 vaccines in KD patients.
This page is intended to collect all the available information coming from Nephrology National societies around Europe and advice on the benefits of vaccination against COVID-19 virus.
Global Kidney Organizations Urge Governments to Prioritize Dialysis Patients for COVID-19 Vaccines
REFERENCES
Kronbichler A, Anders H-J, Fernandez- Juárez GM et al. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrol Dial Transplant 2021 Mar doi.org/10.1093/ndt/gfab064
De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS; NBVN Kidney Registry Group. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. J Am Soc Nephrol. 2021 Feb;32(2):385-396. doi: 10.1681/ASN.2020060875. Epub 2020 Nov 5. PMID: 33154174.
ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94. doi: 10.1093/ndt/gfaa314. PMID: 33340043; PMCID: PMC7771976.
Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020 Dec;16(12):705-706. doi: 10.1038/s41581-020-00349-4. PMID: 32848205; PMCID: PMC7447963.
Ozturk S, Turgutalp K, Arici M et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. 2020 Dec 4:35(12):208302095. doi: 10.1093/ndt/gfaa271.
Hilbrands LB, Duivenvoorden R, Vart P et al for the ERACODA Collaborators. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983. doi: 10.1093/ndt/gfaa261. PMID: 33151337; PMCID: PMC7665620.
